PreComb
PreComb provides a high-throughput, automated platform called 3DTwin® for functional cancer profiling using patient-derived 3D microtumours. The technology generates longitudinal drug response profiles to predict how specific cancers will react to various drugs, doses, and combinations. The company serves oncology drug development teams by supporting candidate prioritization, indication expansion, and rational combination design to reduce translational risk.
Visit websiteHombrechtikon, Switzerland
Healthtech
Biotechnology
Oncology
Drug Discovery
Funding summary
- Total raised
- €2.0M
- Funding rounds
- 2
Investors in PreComb
Investors on record for PreComb. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like PreComb?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors